Engineered lipidic nanomaterials inspired by sphingomyelin metabolism for cancer therapy
Sphingomyelin (SM) and its metabolites are crucial regulators of tumor cell growth,
differentiation, senescence, and programmed cell death. With the rise in lipid-based …
differentiation, senescence, and programmed cell death. With the rise in lipid-based …
Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer
F Davodabadi, S Mirinejad, S Malik, A Dhasmana… - Nanoscale, 2024 - pubs.rsc.org
The long noncoding RNAs (lncRNAs) comprise a wide range of RNA species whose length
exceeds 200 nucleotides, which regulate the expression of genes and cellular functions in a …
exceeds 200 nucleotides, which regulate the expression of genes and cellular functions in a …
Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment
S Lores, M Gámez-Chiachio, M Cascallar… - Biomaterials …, 2023 - pubs.rsc.org
Gene therapy has long been proposed for cancer treatment. However, the use of therapeutic
nucleic acids presents several limitations such as enzymatic degradation, rapid clearance …
nucleic acids presents several limitations such as enzymatic degradation, rapid clearance …
Impacts of TP53TG1 in cancer-associated fibroblasts-derived exosomes on epithelial-mesenchymal transition capacity of colorectal carcinoma cells by targeting miR …
Y Liu, Y Wang, Z Yu, Z Wang - Heliyon, 2024 - cell.com
Objective This research aims at clarifying the action and mechanisms of action of TP53TG1
in cancer-associated fibroblasts (CAF)-derived exosomes (EXs) on colorectal carcinoma …
in cancer-associated fibroblasts (CAF)-derived exosomes (EXs) on colorectal carcinoma …
LncRNA TP53TG1 plays an anti-oncogenic role in cervical cancer by synthetically regulating transcriptome profile in HeLa cells
Y Cheng, N Huang, Q Yin, C Cheng, D Chen… - Frontiers in …, 2022 - frontiersin.org
Long non-coding RNAs (lncRNAs) have been extensively studied as important regulators of
tumor development in various cancers. Tumor protein 53 target gene 1 (TP53TG1) is a …
tumor development in various cancers. Tumor protein 53 target gene 1 (TP53TG1) is a …
In vitro and in vivo evaluation of lipidic nanosystems for cancer therapy
M Cascallar Castro - 2023 - minerva.usc.es
Since the FDA-approval of the first nanomedicines, the development of innovative
therapeutic approaches based on nanotechnology has been continuously growing in the …
therapeutic approaches based on nanotechnology has been continuously growing in the …